Bioline RX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

- On track to report three significant data readouts in next few months - - Completes successful financings, raising gross proceeds of $13.4 million; sufficient to reach multiple important milestones- - Management to hold conference call today, August 6, at 10:00 am EDT - TEL AVIV,.

BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update

TEL AVIV, Israel, July 31, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020,.

BioLineRx to Report Second Quarter 2020 Results on August 6, 2020

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.

BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?

Avinger

Proteostasis Therapeutics

Vaccinex Inc

Viveve Medical

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Bet on Rising Price-to-Earnings With 5 Top Stocks

Alexco Resource

Gold Standard Ventures

Nutanix

Top Ranked Momentum Stocks to Buy for May 29th

TEL AVIV, Israel, May 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled 'BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreatic...

BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine

TEL AVIV, Israel, May 26, 2020 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredited...

BioLineRx Announces $9.0 Million Registered Direct Offering

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2020 Results - Earnings Call Transcript

TEL AVIV, Israel, May 20, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended March 31, 2020 and provides a corporate update. Highlights and...

BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

BioLineRx Concludes Recruitment in Pancreatic Cancer Study

How To Play BioLineRx In 2020

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q3 2019 Results - Earnings Call Transcript

BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q2 2019 Results - Earnings Call Transcript

BioLineRx (BLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2019 Results - Earnings Call Transcript

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2018 Results - Earnings Call Transcript

News for Bioline RX Stock (BLRX)